Last updated: September 27, 2026
FD&C Blue No. 1 Aluminum Lake is a regulated pharmaceutical colorant rather than a conventional active pharmaceutical ingredient. Its market is fragmented, price-sensitive, and driven by finished-dose manufacturing, color consistency, regulatory compliance, and supply reliability. Public companies do not generally report revenue for this product separately, so no authoritative standalone market size or company-specific revenue forecast exists.
The product has no conventional drug-patent exclusivity, no Orange Book listing, and no biosimilar pathway. Its commercial defensibility depends on regulatory approvals, batch certification, technical specifications, customer qualification, and manufacturing quality systems.
What is FD&C Blue No. 1 Aluminum Lake?
FD&C Blue No. 1 Aluminum Lake is the insoluble aluminum-lake form of FD&C Blue No. 1, also known as Brilliant Blue FCF and commonly associated with Color Index 42090. The dye is precipitated onto an aluminum-containing substrate to create a pigment with limited water solubility.
The lake form is used when manufacturers need color that remains dispersed in a solid dosage form, coating, capsule shell, or other low-moisture system. It differs from water-soluble FD&C Blue No. 1, which is more suitable for liquid formulations and aqueous processing.
| Attribute |
FD&C Blue No. 1 Aluminum Lake |
| Substance type |
Aluminum-lake color additive |
| Common color name |
Brilliant Blue FCF Lake |
| Color Index |
CI 42090, commonly associated with Blue 1 |
| Primary pharmaceutical uses |
Tablet coatings, capsule shells, multiparticulates, powders and selected topical or oral products |
| Solubility profile |
Practically insoluble pigment form |
| Regulatory category |
Color additive and pharmaceutical formulation excipient |
| Orange Book status |
Not applicable |
| Drug patent exclusivity |
None as a standalone colorant |
| Biosimilar relevance |
None |
| Main commercial risks |
Regulatory compliance, batch variation, supply continuity, customer qualification |
The exact composition, particle-size distribution, pigment strength, aluminum content, residual solvents, heavy metals, microbiological quality, and dispersion characteristics depend on the supplier specification.
What is the FDA regulatory status of FD&C Blue No. 1 Aluminum Lake?
FDA regulation depends on the specific chemical form, intended use, manufacturing process, and applicable color-additive listing. FD&C Blue No. 1 and its aluminum-lake form are governed through FDA color-additive regulations rather than through an abbreviated or full new-drug application.
FDA’s color-additive framework establishes permitted uses, specifications, certification requirements, and labeling conditions. Relevant provisions appear in Title 21 of the Code of Federal Regulations, including regulations for FD&C Blue No. 1 and its aluminum lake form [1, 2].
Is FD&C Blue No. 1 Aluminum Lake subject to FDA batch certification?
Certification status must be determined against the applicable regulatory provision and supplier material. Certified color additives require FDA lot certification before commercial use in the United States. The purchasing manufacturer normally receives a certification reference, certificate of analysis, and supporting quality documentation.
A pharmaceutical manufacturer should verify:
- FDA color-additive certification status
- Lot-specific certification documentation
- Identity and assay
- Aluminum and heavy-metal limits
- Residual solvents
- Microbial limits
- Particle-size distribution
- Loss on drying or moisture content
- Color strength and shade
- Compliance with current good manufacturing practices
- Change-control commitments
A supplier’s statement that material is “pharmaceutical grade” does not replace confirmation that the specific color additive is authorized for the intended use.
What patents protect FD&C Blue No. 1 Aluminum Lake?
No central composition patent or drug patent protects FD&C Blue No. 1 Aluminum Lake as a commercial colorant. The underlying dye has long been known and is not subject to modern composition-of-matter exclusivity.
Potentially protectable subject matter can include:
- Manufacturing processes
- Particle engineering
- Surface treatment
- Dispersion systems
- Coating compositions
- Improved stability or shade control
- Proprietary premixes
- Formulated color systems
These rights would normally protect a particular process or formulation rather than the use of FD&C Blue No. 1 Aluminum Lake itself.
Does FD&C Blue No. 1 Aluminum Lake have Orange Book patents?
No. The Orange Book covers approved drug products and related patents or exclusivity information. A colorant sold as an excipient or color additive is not independently listed as an Orange Book product [3].
An approved drug containing FD&C Blue No. 1 Aluminum Lake could have patents covering its active ingredient, formulation, manufacturing process, or method of use. Those patents would protect the drug product, not the colorant as a standalone material.
Are there Paragraph IV challenges involving this colorant?
There are no expected Paragraph IV challenges directed to FD&C Blue No. 1 Aluminum Lake as an excipient. Paragraph IV litigation applies to patents listed for approved reference drug products in abbreviated new drug application proceedings. A generic manufacturer may use the colorant in a product, but that use does not create a Paragraph IV case concerning the colorant itself.
When does FD&C Blue No. 1 Aluminum Lake lose exclusivity?
It has no pending drug exclusivity period to expire. The commercial material is effectively available from multiple qualified manufacturers and distributors, subject to regulatory compliance and customer qualification.
| Exclusivity category |
Status |
| New chemical entity exclusivity |
Not applicable |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
Not applicable |
| New drug application exclusivity |
Not applicable |
| Orange Book patent term |
Not applicable |
| Paragraph IV exposure |
Not applicable to the excipient itself |
| Biosimilar exclusivity |
Not applicable |
| Regulatory access |
Controlled by color-additive rules and quality compliance |
The relevant commercial barrier is not legal exclusivity. It is the time and cost required to qualify an alternate source in a regulated finished product.
How strong is the patent estate for FD&C Blue No. 1 Aluminum Lake?
The direct patent estate is weak because the colorant is an established commodity-like material. Patent strength can be higher around specialized delivery or processing systems.
| IP layer |
Relative strength |
Commercial significance |
| Core Blue 1 chemical composition |
Low |
Mature chemistry with no meaningful new-product exclusivity |
| Aluminum-lake formation |
Low to moderate |
Process know-how may affect quality and reproducibility |
| Particle-size engineering |
Moderate |
Can influence coating performance and shade uniformity |
| Pharmaceutical coating system |
Moderate to strong |
May be protected in a finished formulation |
| Proprietary premix or dispersion |
Moderate |
Can create switching costs |
| Manufacturing know-how |
Moderate |
Often more important than patents |
| Finished-drug formulation |
Potentially strong |
Protection belongs to the drug sponsor, not the raw colorant supplier |
Trade secrets, validated processes, regulatory files, and customer-specific specifications are likely to provide more practical protection than patents.
What formulations are protected by FD&C Blue No. 1 Aluminum Lake?
The colorant can appear in several formulation categories:
- Film-coated tablets
- Sugar-coated tablets
- Hard gelatin or hypromellose capsules
- Multiparticulate systems
- Granules and pellets
- Oral powders
- Chewable tablets
- Topical dosage forms
- Selected medical devices and diagnostic products
The lake is particularly useful when the manufacturer requires pigment dispersion rather than a fully soluble dye. The commercial value depends on shade intensity, opacity, migration resistance, compatibility with coating polymers, and processing behavior.
Formulation patents may claim a specific drug product that includes the colorant. They can cover the coating composition, concentration range, particle size, pigment-to-polymer ratio, or manufacturing sequence. Those patents do not create exclusive ownership of FD&C Blue No. 1 Aluminum Lake.
What drives demand for FD&C Blue No. 1 Aluminum Lake?
Demand is tied to production volumes for oral solid dosage forms rather than to a standalone therapeutic market.
Pharmaceutical demand drivers
The main demand drivers are:
- Growth in generic and branded tablet and capsule production.
- Use of color coding to distinguish strengths, products, and manufacturers.
- Expansion of film-coating and modified-release dosage forms.
- Demand for consistent appearance across global manufacturing sites.
- Outsourcing to contract development and manufacturing organizations.
- Use in pediatric, chewable, and patient-friendly dosage forms.
Generic pharmaceutical production is commercially important because generic manufacturers produce large volumes but operate under cost pressure. Colorants represent a small share of total tablet cost, yet a change in shade or processing performance can create batch-release and regulatory risks.
Demand constraints
Demand is constrained by:
- Reformulation away from synthetic colorants
- Consumer and regulator scrutiny of artificial colors
- Aluminum-related formulation concerns
- Regional differences in permitted uses
- Limited per-product consumption
- Qualification requirements for alternate suppliers
- Substitution with other blue colorants or non-lake systems
A colorant supplier therefore competes on reliability and documentation more than on molecule-level differentiation.
How does the competitive landscape affect pricing?
The market is likely fragmented across color manufacturers, specialty pigment producers, pharmaceutical excipient suppliers, and distributors. Industry participants may include specialist color manufacturers such as Sensient Colors, Koel Colours, and other regional producers, subject to product availability and jurisdiction-specific approvals.
The product is not a single globally standardized SKU. Suppliers can differentiate through:
- Pharmaceutical-grade documentation
- Color strength
- Shade reproducibility
- Particle-size control
- Low heavy-metal profile
- Regulatory support
- Global supply capacity
- Short lead times
- Technical support for coating systems
- Audit readiness
- Change-control discipline
Pricing generally depends on grade, certification, purchase volume, packaging, region, and qualification status. Public financial filings do not normally disclose revenue or gross margin for FD&C Blue No. 1 Aluminum Lake separately.
What is the financial trajectory for FD&C Blue No. 1 Aluminum Lake?
The most defensible financial outlook is stable, low-growth demand with selective premium pricing for compliant pharmaceutical grades.
| Financial factor |
Expected effect |
| Tablet and capsule volume |
Supports baseline demand |
| Generic-drug price pressure |
Limits raw-material pricing power |
| Regulatory documentation |
Supports premium for qualified suppliers |
| Supplier consolidation |
Can improve pricing power for approved sources |
| Reformulation away from synthetic colors |
Creates medium-term demand pressure |
| Freight and energy costs |
Can cause short-term price volatility |
| Multi-source qualification |
Limits long-term supplier pricing power |
| Custom particle engineering |
Creates higher-margin niches |
Revenue exposure is difficult to quantify because suppliers usually report broader categories such as colors, pharmaceutical ingredients, excipients, or specialty chemicals. An investor cannot reliably derive Blue 1 Lake revenue from public filings without company-specific sales data.
The likely trajectory has three segments:
Base case
Stable pharmaceutical demand, with modest volume growth from solid-dose products and continued replacement purchasing. Pricing remains competitive, while qualified pharmaceutical-grade material retains a premium over industrial or non-pharmaceutical pigment.
Upside case
Demand increases if oral solid dosage production expands, contract manufacturers add capacity, and suppliers secure multi-year agreements with large pharmaceutical customers. Higher-value coated or engineered grades could improve margins.
Downside case
Demand declines if major customers remove synthetic colors, regulators impose tighter restrictions, or manufacturers consolidate around alternate colors. A supply disruption could raise prices temporarily but would also accelerate customer qualification of substitutes.
What geographic coverage applies to FD&C Blue No. 1 Aluminum Lake?
Regulatory acceptance is jurisdiction-specific. A material approved for one market cannot be assumed to be permitted in another.
| Region |
Commercial consideration |
| United States |
FDA color-additive rules, applicable certification, and pharmaceutical quality requirements |
| European Union |
Food and medicinal-product rules apply separately; E-number and aluminum-lake treatment must be checked for the intended use |
| United Kingdom |
Separate post-Brexit regulatory review may apply |
| Canada |
Health Canada color and drug-product requirements apply |
| Japan |
Japanese color-additive and pharmaceutical standards apply |
| India |
National drug and food-color requirements apply |
| China |
Local regulatory and import documentation requirements apply |
In the European Union, Brilliant Blue FCF is associated with E133, but food authorization does not automatically establish pharmaceutical use for every formulation. The specific lake form, product category, and national implementation must be reviewed against applicable rules [4].
What manufacturing and IP barriers affect supply?
The principal barriers are operational rather than patent-based.
A new supplier may need to demonstrate:
- Reproducible shade and color strength
- Control of aluminum substrate characteristics
- Low contamination profile
- Reliable batch-to-batch particle size
- Validated cleaning and segregation controls
- Pharmaceutical quality-system compliance
- Stability data
- Audit readiness
- Regulatory support
- Continuity of supply
Customer switching can take months or longer because the excipient may affect coating parameters, dissolution, appearance, stability, and regulatory filings. This creates practical supplier retention even where no patent exists.
What generic launch risks exist?
FD&C Blue No. 1 Aluminum Lake does not normally create a standalone generic-launch barrier. Generic launch risks arise from the finished product:
- Listed formulation patents
- Drug-substance patents
- Method-of-use patents
- Paragraph IV litigation
- Color-matching requirements
- Inactive-ingredient differences
- ANDA amendment requirements
- Manufacturing-site qualification
- Supplier discontinuation
- Regional color restrictions
A generic sponsor may use a different colorant, but changing the color system can affect bioequivalence-supporting documentation, product appearance, manufacturing validation, and regulatory review.
Key Takeaways
- FD&C Blue No. 1 Aluminum Lake is a regulated pharmaceutical colorant, not an independently protected drug substance.
- It has no standalone Orange Book listing, Paragraph IV exposure, biosimilar pathway, or conventional drug exclusivity.
- The core chemical and colorant market is mature and relatively commoditized.
- Practical competitive advantages come from certification, quality consistency, technical support, and qualified supply capacity.
- Public companies do not separately disclose revenue for this colorant, preventing a reliable standalone market-size or revenue forecast.
- Demand should remain linked to oral solid dosage production, while synthetic-color reformulation is the main structural downside risk.
- Manufacturing know-how and customer qualification are more important than core composition patents.
FAQs About FD&C Blue No. 1 Aluminum Lake
Is FD&C Blue No. 1 Aluminum Lake the same as Brilliant Blue FCF?
It is the aluminum-lake form of Brilliant Blue FCF, commonly identified with FD&C Blue No. 1 and Color Index 42090. The lake has lower water solubility than the dye form.
Can FD&C Blue No. 1 Aluminum Lake be used in tablets?
Yes, where the specific material and intended use comply with applicable regulatory requirements. It is commonly used in tablet coatings, capsule shells, and other solid dosage forms.
Is FD&C Blue No. 1 Aluminum Lake listed in the FDA Inactive Ingredient Database?
The FDA Inactive Ingredient Database is product- and route-specific. A manufacturer must confirm the exact ingredient name, route, dosage form, and maximum potency against the current database rather than relying on a general colorant reference [5].
Can a pharmaceutical company switch suppliers without regulatory work?
No. Supplier changes generally require qualification, comparative testing, quality review, change control, and potentially regulatory notification or filing updates, depending on the product and jurisdiction.
What is the main investment risk for suppliers of Blue 1 Lake?
The main risk is substitution or reduced use of synthetic colors, not patent expiry. Regulatory changes, customer reformulation, and loss of qualified pharmaceutical accounts can reduce demand.
References
-
U.S. Food and Drug Administration. (n.d.). 21 C.F.R. § 74.101: FD&C Blue No. 1. Electronic Code of Federal Regulations. https://www.ecfr.gov/
-
U.S. Food and Drug Administration. (n.d.). 21 C.F.R. § 82.101: FD&C Blue No. 1 Aluminum Lake. Electronic Code of Federal Regulations. https://www.ecfr.gov/
-
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
European Parliament and Council of the European Union. (2008). Regulation (EC) No. 1333/2008 on food additives. EUR-Lex. https://eur-lex.europa.eu/
-
U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
